These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 31407856)

  • 1. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
    Dekkers CCJ; Sjöström CD; Greasley PJ; Cain V; Boulton DW; Heerspink HJL
    Diabetes Obes Metab; 2019 Dec; 21(12):2667-2673. PubMed ID: 31407856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.
    Mulder S; Heerspink HJL; Darshi M; Kim JJ; Laverman GD; Sharma K; Pena MJ
    Diabetes Obes Metab; 2019 Nov; 21(11):2422-2428. PubMed ID: 31264758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Sodium-Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction.
    Taťána A; Filip M
    Clin Cardiol; 2024 Jul; 47(7):e24303. PubMed ID: 39031990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin (Farxiga) - a new indication for heart failure.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
    Sen T; Scholtes R; Greasley PJ; Cherney DZI; Dekkers CCJ; Vervloet M; Danser AHJ; Barbour SJ; Karlsson C; Hammarstedt A; Li Q; Laverman GD; Bjornstad P; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2022 Aug; 24(8):1578-1587. PubMed ID: 35478433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
    van Bommel EJM; Herrema H; Davids M; Kramer MHH; Nieuwdorp M; van Raalte DH
    Diabetes Metab; 2020 Apr; 46(2):164-168. PubMed ID: 31816432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
    Idzerda NMA; Stefansson BV; Pena MJ; Sjostrom DC; Wheeler DC; Heerspink HJL
    Nephrol Dial Transplant; 2020 Sep; 35(9):1570-1576. PubMed ID: 31005993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
    Iacobellis G; Gra-Menendez S
    Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH
    Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial.
    Sato T; Aizawa Y; Yuasa S; Fujita S; Ikeda Y; Okabe M
    J Atheroscler Thromb; 2020 Dec; 27(12):1348-1358. PubMed ID: 32115470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
    Ott C; Jumar A; Striepe K; Friedrich S; Karg MV; Bramlage P; Schmieder RE
    Cardiovasc Diabetol; 2017 Feb; 16(1):26. PubMed ID: 28231831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.